Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892890 | 0.77 | — | — | |
| SCHEMBL17589207 | 0.75 | BRPF1 (0.34) | — | |
| SCHEMBL14174736 | 0.73 | HRH3 (0.33) | — | |
| SCHEMBL13101100 | 0.72 | CA12 (0.38) | — | |
| SCHEMBL2756221 | 0.71 | — | — | |
| SCHEMBL24127036 | 0.71 | FAAH (0.31) | TSHR | |
| SCHEMBL23772029 | 0.70 | TDP1 (0.39) | — | |
| SCHEMBL17589203 | 0.69 | RXFP1 (0.33) | — | |
| SCHEMBL23772030 | 0.68 | LMNA (0.41) | — | |
| SCHEMBL20033218 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230002769-A1 | APTAMER NUCLEIC ACID MOLECULE, AND COMPLEX AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220214351-A1 | FLUORESCENT DYE, PREPARATION METHOD AND USES THEREOF | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11114251-B2 | Polymer, method for preparing the same and solar cell comprising the polymer | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160225999-A1 | ORGANIC-INORGANIC HYBRID PHOTOELECTRIC CONVERSION DEVICE INCLUDING CONDUCTIVE ORGANIC SEMICONDUCTOR COMPOUND AND METHOD FOR MANUFACTURING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-04 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20120187385-A1 | Conjugated Polymers and Their Use in Optoelectronic Devices | RAYNERGY TEK INC. (TW) | 2012-07-26 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | INMT 1203/4885TSHR 1971/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | INMT 1203/4885TSHR 1971/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | INMT 983/4885TSHR 3209/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | INMT 1203/4885TSHR 1971/4885 |
| US-20230002769-A1 | APTAMER NUCLEIC ACID MOLECULE, AND COMPLEX AND APPLICATION THEREOF | DNTT, TIA1, TIAL1 | INMT 2247/4885TSHR 1081/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | INMT 3298/4885TSHR 3994/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | INMT 3836/4885TSHR 2692/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | INMT 1670/4885TSHR 1328/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | INMT 983/4885TSHR 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.